A novel drug candidate to deter oxycodone abuse.
View complete product pipeline
April 23, 2014DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference Call
April 01, 2014DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting
February 27, 2014DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
February 18, 2014DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
February 12, 2014DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)